Update on the pathogenesis and treatment of the antiphospholipid syndrome : Current Opinion in Rheumatology

Secondary Logo

Journal Logo

SYSTEMIC LUPUS ERYTHEMATOSUS AND SJÖGREN'S SYNDROME: Edited by Mariana J. Kaplan

Update on the pathogenesis and treatment of the antiphospholipid syndrome

Chighizola, Cecilia Beatricea,b; Raschi, Elenaa; Borghi, M. Oriettaa,b; Meroni, Pier Luigia,b

Author Information
Current Opinion in Rheumatology 27(5):p 476-482, September 2015. | DOI: 10.1097/BOR.0000000000000200

Abstract

INTRODUCTION

The updated classification criteria of the antiphospholipid syndrome (APS) require a history of vascular thrombosis and/or pregnancy morbidity in the persistent positivity for serum antiphospholipid antibodies (aPLs). The laboratory detection of circulating aPLs still relies on the solid-phase assays for antibodies against cardiolipin (aCL) and β2 glycoprotein I (anti-β2GPI antibodies) and the functional test lupus anticoagulant [1]. None of the emerging aPL assays nor any of the several manifestations increasingly recognized as part of the APS spectrum are thus considered in these criteria, which date back to 2006 [2▪▪,3▪▪]. Therefore, the formal laboratory and clinical diagnosis of APS does not yet take into account the many advancements in the APS field, which have been allowing the progressive identification of new potential diagnostic markers, the unravelling of aPL antibody-mediated pathogenic mechanisms and the development of novel therapeutic strategies. The most recent and innovative findings about aPL biologic effects and APS treatment will be hereby critically appraised.

F1-9
Box 1:
no caption available

PATHOGENESIS

Anti-β2GPI domain I antibodies

Antiphospholipid antibodies do not provide merely serum APS biomarkers, but rather exert a direct pathogenic role in both vascular and obstetric events. Antibodies reacting against β2GPI, in particular those targeting the immuno-dominant epitope in the N-terminal domain I of the molecule, have been identified as the aPL subset mediating aetio-pathogenic mechanisms [4]. A direct demonstration of the pathogenic effect of anti-domain I antibodies has been recently obtained using anti-beta 2 glycoprotein I minibody (MBB2) – a human monoclonal IgG antibody targeting β2GPI–domain I. Its infusion induced fetal losses in pregnant mice and blood clots in rat mesenteric microcirculation after lipopolysaccharide (LPS) priming. A parent monoclonal antibody – MBB2ΔCH2 – displays the same antigen specificity of MBB2, but lacks the CH2 domain, being unable to activate complement. This might have relevant therapeutic implications: MBB2ΔCH2 has been shown to prevent aPL pro-coagulant and pro-abortive effects in vivo by competing with autoantibodies for binding to β2GPI. MBB2ΔCH2 might be exploited as a therapeutic tool even in obstetric APS as it does not affect the expression of placental β2GPI, which exerts a physiological role in embryo implantation and placental morphogenesis [5▪▪]. Another pioneer therapeutic option exploiting the pathogenicity of anti-domain I antibodies envisages the use of tolerogenic dendritic cells (tDCs) pulsed with both the whole β2GPI molecule and β2GPI–domain I. Infusion of tDCs to β2GPI-immunized BALB/c mice resulted in an efficient reduction of the fetal loss rate by induction of T-regulatory cells, decreased anti-β2GPI antibody titres and raised expression of anti-inflammatory cytokines. Interestingly, a better beneficial effect was obtained with dendritic cells pulsed with domain I than with the whole molecule [6▪].

In line with the hypothesis of anti-domain I antibodies as the main aPL pathogenic subset, patients at higher clinical risk, namely those with triple aPL-positivity, have been shown to display higher anti-β2GPI–domain I antibody titres compared with double/single aPL-positive patients [7▪▪]. Consistently, almost all anti-β2GPI–domain I IgG positivities were confirmed after 12 weeks, at variance of innocent aPL transiently occurring as immune epiphenomenon during infectious diseases. It is thus not surprising if the most recent studies have further confirmed the role of anti-domain I antibody positivity as a strong predictor of thrombotic events and, to a lesser extent, of pregnancy complications. Noteworthy, up to one-third of patients carrying anti-β2GPI antibodies were negative for anti-domain I IgG [7▪▪,8]; the observation that a consistent rate of APS patients display autoantibodies reacting with β2GPI epitopes other than domain I was confirmed in a multi-centre study [9] using several peptides spanning the different domains of the molecule.

Therefore, the replacement of the test using the whole molecule with anti-domain I assay could not yet be advocated because of possible misdiagnosis; on the contrary, anti-domain I antibodies provide a promising second-line test for a better risk-stratification of clinical events.

Cell receptors for β2GPI/anti-β2GPI antibodies

In-vitro studies focusing on the interaction of circulating aPLs with target cells convincingly identified AnnexinA2 and Toll-like receptor (TLR)4 as receptors for whole β2GPI [10]. Novel insights allow further characterization of β2GPI interaction with TLR4: β2GPI was found to bind to cells expressing TLR4 as the only membrane receptor, being then internalized into the cytoplasm [11▪▪]. In addition, TLR4 emerged as the key player in driving endothelial perturbation: tlr4 but not annexinA2-silencing prevented the up-regulation of adhesion molecules. Conversely, β2GPI binding to endothelial cells was reduced in both conditions – a paradox explained by the fact that AnnexinA2 is not a trans-membrane protein. To note, co-silencing for both receptors did not elicit a complete inhibition of anti-β2GPI antibody binding, a finding that fits well with the possibility that additional surface molecules may be involved in β2GPI binding [11▪▪]. Such hypothesis has been explored in few studies: TLR1, TLR2 and TLR6 have indeed been appointed as candidate β2GPI co-receptors in addition to the ones previously reported [11▪▪]. The role of TLR2 and TLR4 has been confirmed in a recent ex-vivo study [12]: an increased mRNA expression of these innate immunity receptors and a markedly raised phosphorylation level of interleukin-1 receptor-associated kinase 1 (IRAK-1) – a major mediator in TLR transduction pathway – were observed in peripheral blood mononuclear cells (PBMCs) from APS patients. Consistently, TLR1, TLR2 and TLR6 have been shown to co-localize with aPL IgG; in addition, antibodies blocking TLR1, TLR2 and TLR6 decreased aPL-mediated up-regulation of tumour necrosis factor (TNF) and tissue factor (TF) in human monocytes [13]. The lack of evidence in support of the TLR4 role emerged in this study might be ascribable to a cell-specific orchestra of receptors, co-receptors and accessory molecules deputed to aPL binding. Since β2GPI specifically binds to LPS via its domain V, it has been proposed that such a binding might account for TLR4 engagement [14]. To rule out this hypothesis, in-vitro experiments were conducted in the presence of increasing amounts of exogenous LPS. Only high endothelial cell-activating LPS concentrations affected β2GPI–TLR4 interaction. This in-vitro evidence helps in understanding why LPS is required both to enhance β2GPI distribution in vascular tissues and to induce clotting in animal models. It can be speculated that the amount of β2GPI on the resting endothelium is not enough to allow sufficient aPL binding to trigger clotting, whereas LPS may increase its vascular distribution up-regulating TLR2 and, to a greater extent, TLR4 [11▪▪].

Since the main source of LPS in healthy individuals is the gut, it might be envisaged that the resident microbiota might affect LPS uptake. Gut microbiota is indeed increasingly recognized as a major player in the development of autoimmunity; commensal bacteria might contribute to APS pathogenesis inducing autoreactive CD4+ T cells and anti-β2GPI antibody production, via molecular mimicry mechanisms or favouring conformational changes in β2GPI, ultimately inducing autoantibody production. Consistent evidence comes from in-vivo models: depletion of gut microbiome with broad-spectrum antibiotics in APS-prone animals markedly prevented thrombotic events, increased survival and reduced anti-β2GPI IgG titres [15].

Intracellular signalling mediators engaged by anti-β2GPI antibodies

Upon engagement of β2GPI receptors on target cells, anti-β2GPI antibody binding results in the activation of intracellular mediators such as nuclear factor kappa B (NF-κB) and p38 mitogen-activated protein kinase (p38MAPK). The cellular steps leading to NF-κB translocation in monocytes have been recently clarified: aPLs engaged NF-κB via a clathrin-dependent endocytic pathway, a mechanism that requires CD14 (TLR4 co-receptor) and AnnexinA2 [13]. NF-κB might also provide a potential future pharmacological target: in BALB/c mice, treatment with a specific NF-κB inhibitor, Dehydroxymethylepoxyquinomicin, prevented aPL-mediated thrombus formation [16]. The above discussed intracellular mediators recruited by anti-β2GPI antibodies are schematically represented in Fig. 1.

F2-9
FIGURE 1:
A schematic overview of the most recent insights into the intracellular pathways engaged by anti-β2GPI antibodies in target cells. β2GPI, β2 glycoprotein I; anti-β2GPI, anti-β2GPI antibodies; DI, domain I; IRAK-1, interleukin-1 receptor-associated kinase 1; mTOR, mammalian target of rapamycin; MyD88, myeloid differentiation primary response 88; NF-κB, nuclear factor kappa B; p38MAPK, p38 mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase; S6RP, S6 ribosomal protein; TF, tissue factor; TLR, Toll-like receptor; TNF, tumour necrosis factor.

The heterogeneity in the clinical spectrum of APS, with some thrombotic APS women experiencing uneventful pregnancies and obstetric APS patients never developing vascular events, suggests that IgG from thrombotic versus obstetric patients might elicit different biological effects. In-vitro support for this intriguing theory has been raised using monocytes [17] and, most recently, first-trimester trophoblast cells. IgG from neither obstetric nor thrombotic APS patients altered the mRNA levels of myeloid differentiation primary response 88 (MyD88), the expression of interleukin (IL)-6 and IL-8 or the phosphorylation rate of p38MAPK, NF-κB and extracellular signal-regulated kinase. Nevertheless, aPLs obtained from women with pure pregnancy manifestations, at variance of those purified from thrombotic patients, significantly reduced trophoblast invasion, an effect that appeared to be mediated by TLR4 [18▪].

The phosphatidylinositol 3-kinase (PI3K)–AKT pathway has been recently identified as an additional signalling cascade engaged by aPLs. It culminates in the recruitment of mammalian target of rapamycin (mTOR), a kinase modulating cellular growth, proliferation and apoptosis. In human microvascular endothelial cells, stimulation with aPL IgG resulted in PI3K-mediated activation of two components of the mTOR pathway: S6 ribosomal protein (S6RP) and AKT [19▪]. These findings were confirmed at immunostaining: the phosphorylation rate of both S6RP and AKT was markedly increased in vascular endothelial cells in renal specimens from APS patients with aPL nephropathy and in the carotid and left anterior descending arteries of catastrophic APS [catastrophic antiphospholipid syndrome (CAPS)] patients. mTOR pathway might therefore mediate the intimal hyperplasia leading to chronic vasculopathy characteristic of both conditions. Given the in-vitro effectiveness of two mTOR inhibitors, PP242 and sirolimus, in preventing the recruitment of S6RP and AKT, sirolimus was prescribed to patients with APS nephropathy undergoing kidney transplantation who developed no vascular lesion recurrence and, compared with patients in the standard regimen arm, displayed a higher rate of functioning allograft at 144 months and a decreased vascular proliferation on biopsy [19▪]. A potential caveat of such approach is provided by the pro-thrombogenicity of mTOR inhibitors emerged in some studies [19▪,20]; the therapeutic relevance of sirolimus warrants confirmation in APS patients with the commonest clinical manifestations.

The role of complement in antiphospholipid syndrome pathogenesis

Apart from anti-β2GPI antibodies, a key role in APS pathogenesis is played by complement. The involvement of the complement cascade is confirmed by the failure of the monoclonal anti-domain I MBB2 to induce vascular thrombosis in C6-deficient rats and fetal loss in C5-depleted mice [5▪▪]. Indirect evidence comes also from the in-vivo effectiveness of pharmacological tools acting on C5: the non-complement-fixing anti-domain I monoclonal MBB2ΔCH2 was shown to inhibit in-vivo effects induced by aPL infusion [5▪▪], the complement C5-inhibitor rEV576 covers in inhibited aPL-mediated venous thrombosis and TF production in a preclinical mouse model [21].

TREATMENT

Thrombotic antiphospholipid syndrome

Anticoagulation, mostly with vitamin K antagonists (VKAs), provides the mainstay of management of thrombotic APS. However, long-term treatment with VKA exerts a strong impact on the quality of life of patients, because of the necessity of frequent INR monitoring, the interaction with foods and drugs and the fluctuation due to alcohol assumption, inter-current illness, exercise and smoking. To overcome these limitations, new-generation, highly selective oral anticoagulants inhibiting a single enzyme of the coagulation cascade were developed. Clinical experience with these direct oral inhibitors (DOIs) in APS is still limited to small case series, even though several randomized clinical trials using rivaroxaban are currently ongoing [22]. However, caution should be paid when prescribing DOI to APS patients: recently, five cases of thrombotic recurrence upon switching from warfarin to rivaroxaban have been described [23,24].

To date, most pharmacological agents in APS counteract aPL-mediated effects by preventing coagulation; alternative strategies are offered by biological agents such as rituximab and eculizumab [25▪▪]. The latter – a humanized monoclonal antibody that binds to the C5 protein with high affinity – has been recently exploited in severe APS cases; in particular, there are reports of favourable outcomes in CAPS, a condition with a high mortality rate and few therapeutic options [26]. Furthermore, eculizumab has been employed in the management of APS patients after renal transplantation: in a case series of three patients treated with anticoagulation and eculizumab, no systemic thrombotic events or early graft losses were reported after a follow-up ranging from 4 months to 4 years [27].

Obstetric antiphospholipid syndrome

The current treatment of all pregnant APS patients encompasses low-molecular weight heparin (LMWH) and low-dose aspirin (LDASA); thanks to this combo regimen, 78% of women deliver a viable infant [28]. However, it is increasingly acknowledged that aPL-positive women might be clustered in two clinical subsets potentially benefitting from different therapeutic approaches. Indeed, women with high-risk triple aPL-positivity usually experience severe late pregnancy complications, while women with a history of recurrent early miscarriages tend to carry low-risk aPL profile, such as a low-titre (below the threshold considered in the updated APS classification criteria) or single positive aPL test. Surely single aPL-positivity should not be neglected in the context of obstetric APS: in the European registry, 67% of included women had a single aPL-positivity [28]. Recent data suggest that the standard regimen might be effective in low-titre aPL-positive early miscarriages, but might be not be enough in the management of late events associated with high-titre aPLs [29▪,30]. Consistently, patients with triple aPL-positivity and a history of thrombosis have been reported to benefit from additional therapies: a 100% live birth rate was achieved with intravenous immunoglobulin and low-dose steroids on the top of standard treatment [31▪▪], an approach that led to successful pregnancy outcomes even in women with refractory obstetric APS [29▪,32▪].

Hydroxychloroquine (HCQ) provides another option in refractory obstetric APS: its addition to standard treatment allowed a decrease in the rate of pregnancy wastage from 81 to 19% [33▪]. Such clinical efficacy is consistent with its well known in-vitro properties: HCQ not only reduces aPL binding to syncytiotrophoblasts and restores the placental expression of AnnexinA5 [25▪▪], but also down-regulates TLR4 expression, thus preventing the anti-β2GPI antibody-induced impairment of trophoblast differentiation [34] and reverses aPL-induced inhibition of pro-migratory IL-6, thus enhancing trophoblast migration [35].

Similarly, vitamin D replacement might be prescribed on top of treatment to women with obstetric APS, in particular those with recurrent pregnancy loss. Indeed, 47.4% of women with pregnancy wastage display low serum vitamin D levels [36]. The potential efficacy of vitamin D in obstetric APS is further suggested by in-vitro evidence: vitamin D, either alone or in combination with LMWH, attenuated aPL-induced cellular inflammatory responses in trophoblast and inhibited LMWH-induced release of the anti-angiogenic factor soluble fms-related tyrosine kinase 1 [37▪].

Asymptomatic antiphospholipid antibody carriers

The clinical management of aPL carriers who have never experienced a thrombotic event is still highly debated. LDASA provides the main therapeutic option; unfortunately, the very low rate of thrombotic events in this population prevents the drawing of definitive conclusions about the efficacy of thromboprophylaxis. However, a recent meta-analysis considering 11 studies for a total of 1208 patients evinced a protective effect of LDASA against the first vascular event among asymptomatic aPL patients, lupus patients and women with obstetric APS [38▪]. Statins might provide another option to be reserved to aPL carriers: consistently with its in-vitro action [25▪▪], fluvastatin was reported in a recent ex-vivo study [39▪] to reduce the serum levels of several pro-inflammatory and pro-thrombotic parameters. LDASA and statins, together with HCQ, thus provide the therapeutic options to be reserved to asymptomatic aPL carriers.

CONCLUSION

Research has been lately galvanized to identify novel pathogenic mediators engaged by aPLs, aiming at identifying novel therapeutic targets. Unfortunately, the development of highly selective pharmacological agents, for example, targeting β2GPI, competing with aPLs for β2GPI or inhibiting signalling mediators, and their introduction in clinical practice, will not take place in the near future. For the time being, it would be interesting to clearly assess the effects on disease control of pleiotropic agents such as HCQ, statins and vitamin D, in addition to standard treatment; preliminary results from the clinical trials on rivaroxaban are expected shortly.

Furthermore, a personalized treatment strategy might be tailored upon the risk profile, which should take into account second-line assays as antibodies against anti-domain I or aPLs of IgA isotype. Anti-β2GPI IgA might even provide a marker of seronegative APS, since this test has been shown to identify patients with manifestations highly suggestive of APS, but no consensus aPLs [40–42].

Although the scenario in APS diagnosis has been static for almost 10 years, the lively and intense research on aPL pathogenic mechanisms has allowed the identification of novel biomarkers, prompting the revision of the classification criteria of the syndrome.

Acknowledgements

None.

Financial support and sponsorship

Funding: None.

Conflicts of interest

There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

  • ▪ of special interest
  • ▪▪ of outstanding interest

REFERENCES

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295–306.
2▪▪. Bertolaccini ML, Amengual O, Andreoli L, et al. 14th International Congress on antiphospholipid antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 2014; 13:917–930.

This study from the latest International Task Force discusses available evidence on the laboratory assays to detect antiphospholipid antibodies, focusing on both criteria and novel tests.

3▪▪. Abreu MM, Danowski A, Wahl DG, et al. The relevance of ‘noncriteria’ clinical manifestations of antiphospholipid syndrome: 14th International Congress on antiphospholipid antibodies Technical Task Force Report on antiphospholipid syndrome clinical features. Autoimmun Rev 2015; 14:401–414.

This study from the latest International Task Force offers an update on the manifestations that are increasingly recognized as part of the clinical spectrum of APS, but are still not included in the classification criteria.

4. Chighizola CB, Gerosa M, Meroni PL. New tests to detect antiphospholipid antibodies: antidomain I beta-2-glycoprotein-I antibodies. Curr Rheumatol Rep 2014; 16:402–409.
5▪▪. Agostinis C, Durigutto P, Sblattero D, et al. A noncomplement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood 2014; 123:3478–3487.

This in-vivo study further highlights the pathogenicity of antibodies targeting domain I of β2GPI. In addition, a monoclonal antibody against domain I not able to activate complement is presented for the first time as a potential therapeutic tool in thrombotic and obstetric manifestations.

6▪. Zandman-Goddard G, Pierangeli SS, Gertel S, Blank M. Tolerogenic dendritic cells specific for β2-glycoprotein-I Domain-I, attenuate experimental antiphospholipid syndrome. J Autoimmun 2014; 54:72–80.

Tolerogenic dendritic cells specific for domain I of β2GPI are suggested as a novel therapeutic approach for APS.

7▪▪. Pengo V, Ruffatti A, Tonello M, et al. Antiphospholipid syndrome: antibodies to domain 1 of β2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost 2015; doi: 10.1111/jth.12865.

In this study, positivity for anti-domain I antibodies consistently confirmed at 12 weeks identifies patients at highest risk of developing thromboembolic events.

8. Andreoli L, Chighizola CB, Nalli C, et al. Antiphospholipid antibody profiling: the detection of IgG antibodies against β2glycoprotein I domain 1 and 4/5 offers better clinical characterization. Arthritis Rheumatol 2015. doi: 10.1002/art.39187 (in press).
9. Artenjak A, Locatelli I, Brelih H, et al. Immunoreactivity and avidity of IgG antiβ2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of β2-glycoprotein I. Immunol Res 2015; 61:35–44.
10. Meroni PL, Chighizola CB, Rovelli F, Gerosa M. Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther 2014; 209:1–14.
11▪▪. Raschi E, Chighizola CB, Grossi C, et al. β2-glycoprotein I, lipopolysaccharide and endothelial TLR4: Three players in the two hit theory for antiphospholipid-mediated thrombosis. J Autoimmun 2014; 55:42–50.

This in-vitro study provides novel insights into TLR4 engagement by β2GPI; noteworthy, this interaction appears not to be LPS-dependent in endothelial cells.

12. Benhamou Y, Bellien J, Armengol G, et al. Role of Toll-like Receptors 2 and 4 in mediating endothelial dysfunction and arterial remodeling in primary arterial antiphospholipid syndrome. Arthritis Rheumatol 2014; 66:3210–3220.
13. Brandt KJ, Fickentscher C, Boehlen F, et al. NF-κB is activated from endosomal compartments in antiphospholipid antibodies-treated human monocytes. J Thromb Haemost 2014; 12:779–791.
14. Laplante P, Amireault P, Subang R, et al. Interaction of β2-glycoprotein I with lipopolysaccharide leads to Toll-like receptor 4 (TLR4)-dependent activation of macrophages. J Biol Chem 2011; 286:42494–42503.
15. Ruff WE, Vieira SM, Kriegel MA. The Role of the gut microbiota in the pathogenesis of antiphospholipid syndrome. Curr Rheumatol Rep 2015; 472:1–10.
16. Nishimura M, Nii T, Trimova G, et al. The NF-κB specific inhibitor DHMEQ prevents thrombus formation in a mouse model of antiphospholipid syndrome. J Nephropathol 2013; 2:114–121.
17. Lambrianides A, Carroll CJ, Pierangeli SS, et al. Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. J Immunol 2010; 184:6622–6628.
18▪. Poulton K, Ripoll VM, Pericleous C, et al. Purified IgG from patients with obstetric but not IgG from nonobstetric antiphospholipid syndrome inhibit trophoblast invasion. Am J Reprod Immunol 2014; 73:390–401.

This study suggests that antibodies purified from patients with thrombotic versus pure obstetric clinical manifestations may elicit different in-vitro biological effects in trophoblast cells.

19▪. Canaud G, Bienaimé F, Tabarin F, et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med 2014; 371:303–312.

The in-vitro and in-vivo experiments presented in this study support the involvement of mTOR pathway in the APS, proposing sirolimus – a mTOR inhibitor – as a potential pharmacological tool in patients undergoing renal transplantation.

20. Van Laecke S, Nagler EV, Vanholder R. Inhibition of the mTORC Pathway in the antiphospholipid syndrome. N Engl J Med 2014; 371:1553.
21. Romay-Penabad Z, Carrera Marin A, Willis R, et al. Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies. Lupus 2014; 23:1324–1326.
22. Chighizola CB, Moia M, Meroni PL. New oral anticoagulants in thrombotic antiphospholipid syndrome. Lupus 2014; 23:1279–1282.
23. Son M, Wypasek E, Celinska-Lowenhoff M, Undas A. The use of rivaroxaban in patients with antiphospholipid syndrome: a series of 12 cases. Thromb Res 2015; 135:1035–1036.
24. Schaefer JK, McBane RD, Black DF, et al. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost 2014; 112:947–950.
25▪▪. Erkan D, Aguiar CL, Andrade D, et al. 14th International Congress on Antiphospholipid Antibodies Task Force Report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014; 13:685–696.

This report from the latest International Task Force extensively reviews all the therapeutic options – from the established to the cutting edge ones – that might be considered in the management of patients with antiphospholipid antibodies.

26. Kronbichler A, Frank R, Kirschfink M, et al. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome. Medicine (Baltimore) 2014; 93:e143.
27. Lonze BE, Zachary AA, Magro CM, et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant 2014; 14:459–465.
28. Alijotas-Reig J, Ferrer-Oliveras R, Ruffatti A, et al. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 247 consecutive cases. Autoimmun Rev 2015; 14:387–395.
29▪. Chighizola CB, Gerosa M, Trespidi L, et al. Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome. Expert Rev Clin Immunol 2014; 10:1505–1517.

This recent review covers the everyday therapeutic approaches to pregnant women with antiphospholipid antibodies.

30. Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G, et al. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood 2014; 123:404–413.
31▪▪. Ruffatti A, Salvan E, Del Ross T, et al. Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. Thromb Haemost 2014; 112:727–735.

This retrospective cohort study identifies additional treatments as the only predictor of favourable pregnancy outcome among women with triple antiphospholipid antibody-positivity and a history of thrombosis.

32▪. Watanabe N, Yamaguchi K, Motomura K, et al. Combination therapy with anticoagulants, corticosteroids and intravenous immunoglobulin for women with severe obstetric antiphospholipid syndrome. Clin Exp Rheumatol 2014; 32:299–300.

This case series supports the efficacy of intravenous immunoglobulins on top of standard treatment in the therapeutic management of women with refractory obstetric APS.

33▪. Mekinian A, Lazzaroni MG, Kuzenko A, et al. The efficacy of hydroxychloroquine for obstetrical outcome in antiphospholipid syndrome: data from a European multicenter retrospective study. Autoimmun Rev 2015; 1–5.

This multi-centre retrospective study proposes HCQ as a novel effective tool in the management of refractory obstetric APS.

34. Marchetti T, Ruffatti A, Wuillemin C, et al. Hydroxychloroquine restores trophoblast fusion affected by antiphospholipid antibodies. J Thromb Haemost 2014; 12:910–920.
35. Albert CR, Schlesinger WJ, Viall CA, et al. Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function. Am J Reprod Immunol 2013; 71:154–164.
36. Ota K, Dambaeva S, Han AR, et al. Vitamin D deficiency may be a risk factor for recurrent pregnancy losses by increasing cellular immunity and autoimmunity. Hum Reprod 2014; 29:208–219.
37▪. Gysler SM, Mulla MJ, Stuhlman M, et al. Vitamin D reverses aPL-induced inflammation and LMWH-induced sFlt-1 release by human trophoblast. Am J Reprod Immunol 2014; 73:242–250.

This in-vitro study shows that vitamin D treatment attenuates the inflammatory response induced by antiphospholipid antibodies in trophoblast cells.

38▪. Arnaud L, Mathian A, Devilliers H, et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev 2015; 14:192–200.

According to this recent meta-analysis, low-dose aspirin exerts a protective antithrombotic effect among asymptomatic antiphospholipid antibody patients and women with obstetric APS.

39▪. Erkan D, Willis R, Murthy VL, et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis 2014; 73:1176–1180.

This ex-vivo study reports the reduction of the serum levels of several pro-inflammatory and pro-thrombotic parameters by fluvastatin.

40. Mattia E, Ruffatti A, Tonello M, et al. IgA anticardiolipin and IgA antiβ2 glycoprotein I antibody positivity determined by fluorescence enzyme immunoassay in primary antiphospholipid syndrome. Clin Chem Lab Med 2014; 52:1329–1333.
41. Ruiz-García R, Serrano M, Martínez-Flores JÁ, et al. Isolated IgA anti β2 glycoprotein I antibodies in patients with clinical criteria for antiphospholipid syndrome. J Immunol Res 2014; doi: 10.1155/2014/704395.
42. Cousins L, Pericleous C, Khamashta M, et al. Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with 'seronegative’ antiphospholipid syndrome. Ann Rheum Dis 2015; 74:317–319.
Keywords:

antiphospholipid antibodies; antiphospholipid syndrome; pathogenesis; treatment

Supplemental Digital Content

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.